Drugs / ARO-RAGE
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05533294 | Nov 2022 → Feb 2024 | asthma | Arrowhead Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05276570 | Jun 2022 → Apr 2025 | asthma | Arrowhead Pharmaceuticals | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07241546 | Mar 2026 → Dec 2027 expected | asthma | Arrowhead Pharmaceuticals | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2024-05-20 | Arrowhead Pharmaceuticals | Results Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma arrowheadpharma.com ↗
Interim results from the ongoing Phase 1/2 study demonstrate that treatment with ARO-RAGE led to a reduction in soluble RAGE (sRAGE) concentration in bronchoalveolar lavage fluid (BALF) and serum in a dose-dependent manner in normal healthy volunteers (NHV) and in patients with mild to moderate asthma. |
| 2023-09-11 | Arrowhead Pharmaceuticals | Results Arrowhead Presents Data on Pulmonary Pipeline at ERS 2023 arrowheadpharma.com ↗
In an ongoing Phase 1/2 clinical trial, ARO-RAGE, Arrowhead’s investigational RNAi therapeutic for the treatment of inflammatory lung diseases, achieved mean target gene knockdown of up to 90% with a maximum of 95% after a single inhaled administration. |
| 2023-06-01 | Arrowhead Pharmaceuticals | Results Arrowhead Hosts R&D Day Highlighting Its Pipeline of RNAi Therapeutics arrowheadpharma.com ↗
New clinical data also show ARO-RAGE achieved serum sRAGE reductions in asthma patients consistent with effects seen in healthy volunteers at the 44 mg dose, the only dose level currently available in asthma patient cohorts. |
| 2023-04-25 | Arrowhead Pharmaceuticals | Results Arrowhead Pharmaceuticals’ Proprietary Pulmonary TRiM™ Platform Achieves High Levels of Target Gene Knockdown and Long Duration of Effect arrowheadpharma.com ↗
These interim ARO-RAGE Phase 1/2 data are highly encouraging. |
| 2022-03-15 | Arrowhead Pharmaceuticals | Regulatory Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-RAGE for Treatment of Asthma arrowheadpharma.com ↗ |
All press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-05-20 | Arrowhead Pharmaceuticals | Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma arrowheadpharma.com ↗ |
| 2023-09-11 | Arrowhead Pharmaceuticals | Arrowhead Presents Data on Pulmonary Pipeline at ERS 2023 arrowheadpharma.com ↗ |
| 2023-06-01 | Arrowhead Pharmaceuticals | Arrowhead Hosts R&D Day Highlighting Its Pipeline of RNAi Therapeutics arrowheadpharma.com ↗ |
| 2023-04-25 | Arrowhead Pharmaceuticals | Arrowhead Pharmaceuticals’ Proprietary Pulmonary TRiM™ Platform Achieves High Levels of Target Gene Knockdown and Long Duration of Effect arrowheadpharma.com ↗ |
| 2022-07-05 | Arrowhead Pharmaceuticals | Arrowhead Pharmaceuticals Initiates Phase 1/2a Studies for Two Pulmonary Candidates ARO-MUC5AC and ARO-RAGE arrowheadpharma.com ↗ |
| 2022-03-15 | Arrowhead Pharmaceuticals | Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-RAGE for Treatment of Asthma arrowheadpharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARO-RAGE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05276570 ↗ |
| Route | Inhaled | “by inhalation of nebulized solution” NCT05276570 ↗ |